EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Intravenous Dextrose for the Treatment of Neonatal Hypoglycaemia: A Systematic Review

Lily F Roberts, Libby G Lord, Caroline A Crowther, Jane E Harding, Luling Lin

Neonatology · 2024

DOI: 10.1159/000541471 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neonatology, 2024. Verfasst von Lily F Roberts und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liggins Institute, University of Auckland, Auckland, New Zealand, lily.roberts@auckland.ac.nz. Hauptthemen laut MEDLINE: Hypoglycemia, Glucose, Infant, Newborn, Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hypoglycaemic neonates are usually admitted to neonatal intensive care for intravenous (IV) dextrose infusion if increased feeding and dextrose gel fail to restore normoglycaemia. However, the effectiveness of this intervention is uncertain. This review aimed to assess the evidence for the risks and benefits of IV dextrose for treatment of neonatal hypoglycaemia.

Methods

Four databases and three clinical trial registries were searched from inception to October 5, 2023. Randomised controlled trials (RCTs), non-randomised studies of interventions, cohort studies, and before and after studies were considered for inclusion without language or publication date restrictions. Risk of bias was assessed using Cochrane’s Risk of Bias 2 tool or Risk of Bias in Non-Randomized Studies of Interventions tool. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. Meta-analysis was planned but not carried out due to insufficient data.

Results

Across 6 studies (two RCTs and four cohort), 711 participants were included. Evidence from one cohort study suggests IV dextrose treatment may not be associated with neurodevelopmental impairment at ≥18 months of age (no effect numbers, p > 0.2; very low certainty evidence; 60 infants). Evidence from one RCT suggests IV dextrose treatment may reduce the likelihood of repeated hypoglycaemia (risk ratio [RR]: 0.67 [95% CI: 0.20, 2.18], p = 0.5; low certainty evidence; 80 infants) compared to treatment with oral sucrose bolus. However, the risk of a hyperglycaemic episode may be increased (RR: 2.33 [95% CI: 0.65, 8.39], p = 0.19; 80 infants).

Conclusion

More evidence is needed to clarify the benefits and risks of IV dextrose for treatment of neonatal hypoglycaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoglycemiaGlucoseInfant, Newborn, DiseasesHumansInfant, NewbornInfusions, IntravenousBlood GlucoseRandomized Controlled Trials as TopicAdministration, Intravenous

Stichwörter der Autor:innen

Blood glucoseInfantIntravenous infusionNewborn

Substanzen

GlucoseBlood Glucose

Autor:innen und Institutionen

  • Liggins Institute, University of Auckland, Auckland, New Zealand, lily.roberts@auckland.ac.nz.
  • Liggins Institute, University of Auckland, Auckland, New Zealand.

Förderung

  • NICHD NIH HHS

Zitieren

APA

Roberts, L. F., Lord, L. G., Crowther, C. A., Harding, J. E., & Lin, L. (2024). Intravenous Dextrose for the Treatment of Neonatal Hypoglycaemia: A Systematic Review. Neonatology. https://doi.org/10.1159/000541471

Vancouver

Roberts LF, Lord LG, Crowther CA, Harding JE, Lin L. Intravenous Dextrose for the Treatment of Neonatal Hypoglycaemia: A Systematic Review. Neonatology. 2024. doi:10.1159/000541471

BibTeX
@article{Roberts2024,
  author = {Roberts, Lily F and Lord, Libby G and Crowther, Caroline A and Harding, Jane E and Lin, Luling},
  title = {Intravenous Dextrose for the Treatment of Neonatal Hypoglycaemia: A Systematic Review},
  journal = {Neonatology},
  year = {2024},
  doi = {10.1159/000541471}
}
Kostenlos starten →